Sector News

Novo Nordisk chief Lars Rebien Sorensen to step down early

September 1, 2016
Life sciences

The man who last year topped Harvard Business Review’s “world’s best-performing CEO” ranking will be stepping down from the Danish diabetes company after 16 years on the job.

The departure of Lars Rebien Sorensen also appears to be a departure from its long-term plan, reiterated last year by the company, that was set to see the long-standing chief see out his contract until 2019.

His shoes will from the start of next year be filled by Lars Fruergaard Jorgensen, currently the company’s EVP and head of corporate development.

Jorgensen said: “Succeeding Lars, who during 16 years as CEO of Novo Nordisk has spearheaded Novo Nordisk into a global, very successful and highly respected pharmaceutical company, is a tall order.

“On behalf of Novo Nordisk’s Board of Directors and the company’s employees, I want to thank Lars for his outstanding leadership, steady course and commitment to Novo Nordisk through good and difficult times during his 34 years with the company.”

The company has over the years seen strong growth, but pricing pressure in the U.S. for diabetes medicines, which is its predominant focus, have increased–and a month ago it was forced to cut its forecast for its full-year profit growth. Generic competition to insulin products is also piling on the problems for all diabetes drugmakers.

Göran Ando, the company’s chairman, said Jørgensen had a track record of “creating results, driving change and being a role model for the Novo Nordisk Way of running a company.” He added: “In his new role, he will be charged with leading Novo Nordisk through a time of extraordinary change in healthcare systems around the world, with the company’s long-term strategy, the Triple Bottom Line business principle and long-term financial targets as his guiding posts.

By Ben Adams

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”